Objective
Our overall project is to develop and prepare to commercialise a rapid, cost-effective platform for near-patient diagnosis using multiplex immunoassays.
Development of a cost-effective system for diagnosis by multiplex biomarker analysis at the point-of-care is essential to enable the delivery of modern, stream-lined healthcare systems in the EU and globally that rapidly and accurately assesses patient needs at the earliest opportunity.
Immunoassays are a mainstay of clinical diagnoses. ELISA tests provide sensitive, accurate and quantitative diagnostic data for a large number of disease biomarkers. The technology has not changed for decades and requires central laboratory facilities. Each test measures only one biomarker and takes up to 2 hours to perform.
NALIA Systems’ technology provides multiplexed ELISA tests in which panels of 10-15 biomarkers can be tested in parallel, whilst retaining the sensitivity, accuracy and quantification benefits of standard ELISA tests. The first NALIA Arrays are now being made available for use in laboratories.
Standard ELISA technology cannot be adapted for use at point-of-care due to the time to result and the complex liquid handling needed. In contrast, the inherent characteristics of NALIA’s array technology mean that it can be incorporated into disposable cartridges and dramatically reduce the time to result.
This project will develop a bench-top device and disposable cartridge system for biomarker arrays for diagnosis at the point of care. Initial arrays will be for autoimmune disorders, allergy and infectious diseases, followed by oncology and other diseases.
In Phase 1 we intend to confirm the feasibility of achieving a result in <20min; to prepare a product development plan that will lead to a manufacturable device and series of cartridges; to complete a business plan covering all aspects of the commercial opportunity, pricing, market size, competition and route to market; and submit an application for Phase 2 funding.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences physical sciences classical mechanics fluid mechanics microfluidics
- medical and health sciences health sciences infectious diseases
- medical and health sciences basic medicine immunology autoimmune diseases
- medical and health sciences clinical medicine oncology
- medical and health sciences clinical medicine allergology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
NW9 8UA LONDON
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.